Please login to the form below
leukaemia combo therapy
This page shows the latest leukaemia combo therapy news and features for those working in and with pharma, biotech and healthcare.
AbbVie trial backs chemo-free Imbruvica combo regimen
Imbruvica paired with Roche’s Gazyva for previously untreated CLL patients. The pairing of of AbbVie’s Imbruvica and Roche’s Gazyva has hit the mark in a chronic lymphocytic leukaemia ... or more) with either CLL or small lymphocytic leukaemia (SLL)
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
-
B2B media account director
-
Competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- bluebird bio’s beti-cel accepted for priority review by FDA
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- First trial of a vaccine against Alzheimer’s launches
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Engaging HCPs on their own terms: how pharma can adapt to the post-pandemic digital era
- The UK’s new medicines pricing deal – opportunities and risks for pharma
- Biogen’s Aduhelm unlikely to get approval in Europe
PMHub
M3 (EU)
M3 is the world’s largest network of verified doctors with over 6 million members across key markets; our closed and...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
